CASOS CLÍNICOS

ENDOLEAK TIPO 1A TARDIO APÓS EVAS: UM DESAFIO ÚNICO

LATE TYPE 1A ENDOLEAK AFTER EVAS: AN UNIQUE CHALLENGE

Rita Augusto*1,2, Ricardo Gouveia2, Jacinta Campos1,2, Andreia Coelho1,2, Nuno Coelho1,2, Daniel Brandão1,2, Alexandra Canedo1,2

1. Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
2. Unidade de Angiologia e Cirurgia Vascular da Faculdade de Medicina da Universidade do Porto, Porto, Portugal

Recebido a 10 de maio de 2020
Aceite a 30 de setembro de 2020

RESUMO

Endovascular aneurysm sealing (EVAS) com o auxílio do sistema Nellix é um método alternativo para o tratamento de aneurismas da aorta abdominal (AAA). Os endoleaks tipo 1a podem ocorrer em até 10% dos casos de reparação endovascular de AAA (EVAR). A incidência destes endoleaks pode ir até 3,1%, Segundo descrito na literatura. O diagnóstico precoce e classificação destes endoleaks são cruciais para evitar casos de ruptura do saco aneurismático, previamente descritos. Deste modo, os autores reportam um caso de um endoleak tipo 1a, vinte e quatro meses após realização de EVAS, tratado com sucesso por via endovascular.

Trata-se de um homem de 82 anos de idade, que foi submetido à reparação de um AAA de 55 mm através de EVAS em 2014. A angiografia final demonstrou a exclusão do aneurisma e a ausência de endoleaks. O seguimento pós operatorio foi feito como habitual, através da realização de Angiotec, que demonstravam um correcto posicionamento da prótese, sem sinais de endoleaks e com diminuição progressiva do saco aneurismático. O Angiotec realizado em 2016 demonstrou a presença de novo de um endoleak tipo 1a, associado a um crescimento significativo do saco aneurismático. Face a isto, os autores optaram pela realização de um procedimento endovascular através da embolização do saco com 0,018* detachable coils e Onyx 34. A angiografia final demonstrou a permeabilidade dos componentes da Nellix e a exclusão do endoleak. A incidência e o significado de um endoleak tipo 1a após EVAS foi previamente estudada na literatura, com alguns casos reportados, e a história natural de um endoleak tipo 1a após EVAS pode levar a ruptura do saco aneurismático e consequente morte. A embolização do endoleak com coils e Onyx apresentou-se, neste caso, como uma alternativa eficaz e segura para alcançar o sucesso terapêutico e clínico.

Palavras-chave
Aneurisma da aorta abdominal; endoleak; Onyx 34; EVAS; Nellix

ABSTRACT

Endovascular aneurysm sealing (EVAS) using the Nellix system is an alternative method for abdominal aortic aneurysm (AAA) repair. Type 1 endoleaks are not an uncommon complication following conventional endovascular aortic aneurysm repair (EVAR), occurring in up to 10% of cases. The incidence of these endoleaks following Nellix EVAS was determined to be up to 3,1% in short-term follow-up. Early detection and classification of this issue is crucial to avoid the potential of sac rupture, previously described. As so, we report a successful endovascular treatment of type 1a endoleak, twenty-four months after a Nellix EVAS implantation.

An 82-year-old male underwent a Nellix endovascular repair for a 55 mm infra-renal aortic aneurysm in 2014. Final angiography showed successful aneurysm exclusion with no endoleaks. Regular follow-up using computed tomography angiography (CTA) showed a relatively satisfying good stent graft positioning, no signs of endoleaks and shrinkage of the aneurysm sac. CTA of 2016 showed a new type 1a endoleak associated wit a significant growth of the aneurysm sac. The authors performed prompt embolization of the endoleak with 0,018* detachable coils and Onyx 34. Final angiography showed potency of the endografts with satisfactory exclusion of the endoleak.

*Autor para correspondência.
Correio eletrónico: rita.augusto1988@gmail.com (R. Augusto).
The incidence and significance of type 1 endoleaks following Nellix EVAS was previously studied in literature, with some cases reported and the natural history of untreated type 1 endoleak after EVAS might lead to sac rupture and death. The embolization of the endoleak with coils and Onyx appears to be a safe and effective management choice to achieve technical and clinical success in the treatment of these cases.

**Keywords**

Abdominal aortic aneurysm; endoleak; Onyx 34; EVAS; Nellix system

**INTRODUCTION**

Despite improvements in endograft devices, endoleaks of any type are still the most common complications after endovascular abdominal aortic aneurysm repair (EVAR). Type Ia endoleak following conventional EVAR occurs in up to 10% of cases. These endoleaks usually oblate early re-intervention due to continuing aneurysm sac pressurization and risk of rupture. Endovascular Aneurysm Sealing (EVAR), using the Nellix system (Endologix, Irvine, CA, USA), is a recent and different method for the treatment of infrarenal abdominal aortic aneurysms (AAA). This technique is based on two balloon expandable covered 10-mm chromium-cobalt stents, mounted on identical 17F catheter based delivery systems - which provide a flow lumen in parallel from the non-aneurysmal aorta proximally to the iliac artery distally - that are surrounded by endobags that are filled in situ with a soluble polymer to provide both fixation and seal.

The system was designed in an attempt to reduce complications, particularly endoleaks of any kind - due to the ability of the endobags to fill the aneurysm sac, which may impact surveillance strategies and the need for subsequent aortic re-intervention. The instructions for use (IFU) at its introduction in 2013 included: an infrarenal neck diameter of 18-32 mm, a neck length of 10 mm and neck angle < 60°. After that, the IFU has been redefined to further optimize outcomes with a reduction of neck diameter range to a maximum of 28 mm, reduction of the maximum iliac artery diameter to 20 mm and the addition of an AAA/lumen ratio (≥ 1.4). As the EVAS procedure continued to evolve, a second-generation Nellix device was introduced in 2016 with, amongst other improvements, distal fixation of the endobags to the stents.

The published incidence of endoleak after EVAS is low. Prospective evidence was derived from 2 trials. The Nellix system Investigational Device Exemption (IDE) pivotal trial, that included 142 patients treated inside the IFU, reported a total endoleak rate at 30 days of 6.3% (type I, 0.7%; type II, 5.6%). At 1 year, the persistent endoleak rate was 3.1% (type I, 0.8%; type II, 2.3%).

The EVAS FORWARD Global Registry, which registered 277 patients both inside and outside the IFU, had an early type Ia endoleak in eight cases. Root cause analysis of the type Ia endoleaks suggested that the majority were due to technical aspects of the procedure: implantation of the device caudal to the optimum sealing zone or insufficient polymer filling of the endobags. The 1-year free survival of type Ia endoleak was 96%.

Although the published incidence of endoleak is low in the short-term – 3.1% –, there are increasing concerns about the durability of the Nellix device. The treatment of a type Ia endoleak after EVAS can be challenging and optimal treatment modalities are yet to be defined, although embolization and proximal extension techniques have been suggested. In this context, the authors report a successful endovascular treatment of type Ia endoleak twenty-four months after a Nellix EVAS implantation.

**CASE REPORT**

An 82-year-old male with a prior medical history of hypertension, dyslipidemia and smoking, underwent a Nellix endovascular repair for a 55 mm infra-renal aortic aneurysm in 2014. On preoperative contrast computed tomography (CT) imaging, the AAA had a blood lumen diameter of 42 mm. The proximal aortic neck had a maximum diameter of 24 mm, a length of 20 mm from the lower renal artery. The maximum diameters of the iliac arteries were 13 mm on the right and 18 mm on the left. EVAS was performed within the company’s instructions for use of Nellix. Percutaneous bilateral transfemoral access was obtained using percutaneous approach. Final angiography showed successful aneurysm exclusion with no endoleaks. Regular follow-up using computed tomography angiography (CTA) showed a relatively satisfying good stentgraft positioning, no signs of endoleaks and a shrinkage up to 52 mm of the aneurysm sac – CTA performed at 1, 6, 12 and 24 months. CTA at 24 months follow-up showed a new type Ia endoleak associated with a significant growth of the aneurysm sac up to 58 mm (Figure 1). As so, the authors decided to perform prompt embolization of the referred endoleak.
CTA and US performed at 1 and 6 months after procedure showed no endoleaks and a shrinkage of the aneurysm sac up to 56 mm. Unfortunately, the patient died 15 months after the re-intervention, due to a respiratory infection with sepsis.

**DISCUSSION**

Initial efficacy data on the EVAS technique was encouraging, but the knowledge of its potential complications and their respective managements are limited. Reported adverse events include migration and proximal type 1 endoleak, type 2 endoleaks, graft stenosis and occlusion.

After the commercial release of Nellix in 2013, in the largest cohort of patients to date, Böckler and colleagues reported their experience in 171 cases, performed at multiple European centers and one in New Zealand. Technical success (98.8%) was achieved in all but two patients. They found no intra-operative type 1a endoleaks, but five type 1a endoleaks were detected on follow-up, three after one month and two at six months. One of these resolved spontaneously, two were embolized and two were observed. There was no difference in the aortic neck length in cases with or without type 1a endoleaks (22.7 +/- 12 mm vs 28 +/- 15 mm; p = 0.39). Four of five type 1a endoleaks were seen in the 116 cases within the manufacturer’s IFU and one within the 55 cases outside the IFU. There were four limb occlusions (2.3%). Aneurysm-related re-interventions were performed in nine patients (5.2%) and there were no aneurysm ruptures or surgical conversions.

The data available currently presents the short-term follow-up results and the endoleaks observed may be in part related to technical factors during the deployment, resulting in lower than intended positioning of the proximal graft and insufficient coverage of the proximal neck.

According to EVAS Type IA Endoleak Study Group, post-EVAS type 1a endoleaks after EVAS were categorized as follows: a type Is1 endoleak was defined as the appearance of contrast between the endobag and the aneurysm wall but not reaching the aneurysm sac. This type would not be classified as endoleak within the accepted definitions for EVAR. Type Is2 endoleaks were defined as those where there was contrast between the endobag and aneurysmal wall or thrombus inside the aneurysm sac - as it was shown in this case: a type Is3 endoleak was defined as shoving contrast or newly formed thrombus between the endobags inside the aneurysm sac and a type Is4 endoleak was defined as the presence of sac pressurisation without proof of endoleak or with the presence of secondary signs.

There are no data on the natural history of untreated endoleak following EVAS but it seems intuitive to assume...
that there is a similar potential for sac enlargement and ultimately rupture. In fact, there has been a case report in the literature of a delayed recurrent type 1a endoleak associated with increased aortic sac size and rupture.\(^9\)

Sealing of proximal type 1a endoleaks after an EVAR may be treated by placement of a proximal cuff extension (with or without chimney grafts to the renal and/or visceral arteries), branched/fenestrated EVAR, EndoAnchors, endovascular embolization, or open surgery. Although, these approaches are not possible with the Nellix system for obvious reasons. An alternative approach is transcatheter embolisation with Onyx, which is well established for type 2 endoleaks.\(^9\)

The literature on the management of type 1a endoleak following EVAS is very limited. Partial or total endograft explanation combined with conventional open repair remains an option for patients with a persistent type 1a endoleak that is not amenable to endovascular therapy (including branched or fenestrated solutions).\(^7\)

Ameli-Renani et al. published their experience on embolization of 7 type 1a endoleaks after EVAS – using coils and Onyx in six cases and Onyx only in one case. They obtained a 100% technical success no recurrent endoleaks during the follow-up.\(^8\) One of the concerns related to this treatment is the possibility of Onyx reflux during the injection, which may compromise the patency of the endografts or lead to distal embolization. For this reason, some authors prefer to initially use detachable coils to form a scaffold in the endoleak cavity before completing the procedure with Onyx.\(^8\) A disadvantage of Onyx and coils embolisation is the streak artifact present on follow-up CT imaging which can obscure a recurrence of the endoleak.\(^7\)

Distal migration - the commonest cause of late endoleaks - can be treated with proximal Nellix-in-Nellix extension. This technique, however, has limitations, as the endobags of the Nellix extensions should protrude at least 2 to 3 cm above the primary stent in order to provide good wall apposition. Given this minimum sealing length requirement, parallel grafts for the renal arteries are often required.\(^8\) In patients with caudal migration who still have an adequate length of proximal neck seal, reinforcement of the Nellix stents with rigid, balloon-expandable covered stents might also be of value. In this case, after the image study, we can conclude that the cause of the endoleak was the development of aneurysmal aortic disease in the proximal neck.

Long-term durability of all these re-interventions needs to be confirmed.

According to the literature, Nellix EVAS has also been successfully used to repair failed EVAR, ruptured abdominal aortic aneurysm and iliac artery aneurysms.\(^5\)–\(^8\)

The new revised IFU and latest-generation Nellix promise good results, even though patient applicability is significantly reduced. This needs clinical validation and the continuation of the Nellix EVAS FORWARD clinical trial provides an opportunity for that.\(^9\)

**CONCLUSION**

The incidence and significance of type 1 endoleaks following Nellix EVAS is unknown with few cases reported and there is no data on the natural history of untreated type 1 endoleak after EVAS. Unlike conventional EVAR, the alternatives to treat a type 1a endoleak after EVAS are clearly reduced, transforming it into a difficult therapeutic challenge. Meanwhile, the embolisation of the endoleak with coils and Onyx appears to be a safe and effective management choice to achieve technical and clinical success in the treatment of these cases.

**REFERENCES**


